Pharmaron Beijing Co., Ltd. (SHE:300759)

Market Cap	67.95B +23.3%
Revenue (ttm)	15.25B +16.3%
Net Income	1.71B +24.0%
EPS	0.95 +21.6%
Shares Out	1.84B
PE Ratio	42.38
Forward PE	27.12
Dividend	0.20 (0.47%)
Ex-Dividend Date	Jul 7, 2026

Volume	41,465,793
Open	42.76
Previous Close	41.55
Day's Range	39.66 - 42.76
52-Week Range	21.01 - 53.57
Beta	0.64
Analysts	Buy
Price Target	50.33 (+24.95%)
Earnings Date	Aug 20, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleot...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 27,316
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300759

Financial Performance

In 2025, Pharmaron Beijing's revenue was 14.10 billion, an increase of 14.82% compared to the previous year's 12.28 billion. Earnings were 1.66 billion, a decrease of -7.22%.

Analyst Summary

According to 12 analysts, the average rating for 300759 stock is "Buy." The 12-month stock price target is ¥50.33, which is an increase of 24.95% from the latest price.

Price Target

¥50.33

(24.95% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error